Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P960006/S059

Fixation Tool (Model 6616)

Boston Scientific · Decision date May 15, 2026

FDA DECISIONP960006/S059

What did the FDA decide?

FDA records P960006/S059 as a supplement to PMA P960006, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 15, 2026.

FDA approval order statement

to change sites for ethylene oxide (EO) gas sterilization operations and final packaging activities for the Accessories used with the Cardiac Rhythm Management (CRM) divisions Pulse Generators and Leads.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
May 15, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P960006/S059
Regulatory pathway
PMA supplement
Product code
NVN
Decision code
OK30
Decision date
May 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug eluting permanent right ventricular (RV) or right atrial (RA) pacemaker electrodes.

Product code
NVN
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P960006/S058 · Related supplement

    Fixation Tool Model 6616

  2. P960006/S059 received

    Application receipt date recorded by FDA.

  3. P960006/S059 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P960006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P960006

Product / regulatory recordCompanyPathwayDecision dateSource
Boston ScientificPMA supplementSep 16, 2025FDA
Boston ScientificPMA supplementApr 10, 2026FDA

Explore the linked device profile

Other records with product code NVN

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic Cardiac Rhythm Disease ManagementPMA supplementOct 16, 2026FDA
ABBOTT MEDICALPMA supplementOct 9, 2026FDA
Medtronic Cardiac Rhythm Disease ManagementPMA supplementAug 5, 2026FDA
ABBOTT MEDICALPMA supplementJun 26, 2026FDA
IsoFlex LeadsP960030/S085
ABBOTT MEDICALPMA supplementJun 26, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records